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ABSTRACT
Objectives Develop an individualised prognostic risk 
prediction tool for predicting the probability of adverse 
COVID- 19 outcomes in patients with inflammatory bowel 
disease (IBD).
Design and setting This study developed and validated 
prognostic penalised logistic regression models using 
reports to the international Surveillance Epidemiology of 
Coronavirus Under Research Exclusion for Inflammatory 
Bowel Disease voluntary registry from March to October 
2020. Model development was done using a training data 
set (85% of cases reported 13 March–15 September 
2020), and model validation was conducted using a test 
data set (the remaining 15% of cases plus all cases 
reported 16 September–20 October 2020).
Participants We included 2709 cases from 59 countries 
(mean age 41.2 years (SD 18), 50.2% male). All submitted 
cases after removing duplicates were included.
Primary and secondary outcome measures COVID- 19 
related: (1) Hospitalisation+: composite outcome of 
hospitalisation, ICU admission, mechanical ventilation or 
death; (2) Intensive Care Unit+ (ICU+): composite outcome 
of ICU admission, mechanical ventilation or death; (3) 
Death. We assessed the resulting models’ discrimination 
using the area under the curve of the receiver operator 
characteristic curves and reported the corresponding 95% 
CIs.
Results Of the submitted cases, a total of 633 (24%) 
were hospitalised, 137 (5%) were admitted to the ICU or 
intubated and 69 (3%) died. 2009 patients comprised the 
training set and 700 the test set. The models demonstrated 
excellent discrimination, with a test set area under the 
curve (95% CI) of 0.79 (0.75 to 0.83) for Hospitalisation+, 
0.88 (0.82 to 0.95) for ICU+ and 0.94 (0.89 to 0.99) for 
Death. Age, comorbidities, corticosteroid use and male 
gender were associated with a higher risk of death, while 
the use of biological therapies was associated with a lower 
risk.
Conclusions Prognostic models can effectively predict 
who is at higher risk for COVID- 19- related adverse 
outcomes in a population of patients with IBD. A free 
online risk calculator (https:// covidibd. org/ covid- 19- 
risk- calculator/) is available for healthcare providers to 
facilitate discussion of risks due to COVID- 19 with patients 
with IBD.
INTRODUCTION
Since the onset of the COVID- 19 pandemic, 
almost 50 million cases have been reported 
globally. Many countries, including the USA, 
are reporting record numbers of new cases 
as of November 2020.1 While the majority 
of cases are mild, patients with at least one 
comorbidity are at higher risk of adverse 
outcomes, including hospitalisation, respira-
tory failure or death.2 3 Risk calculators can 
facilitate shared decision making between 
patients and healthcare providers,4 and such 
tools have been created to predict death due 
to COVID- 19 in US patients 65 years and 
older,5 to determine hospitalisation risk6 and 
to guide early vaccine allocation.
Patients with inflammatory bowel disease 
(IBD) are prescribed immunosuppressive 
medications such as corticosteroids, immu-
nomodulators, biological therapies and 
Strengths and limitations of this study
 ► Our study includes data from an international co-
hort with a wide range of ages including paediatric
patients.
 ► The use of regularised regression methods for pre-
diction allowed us to consider a wide range of po-
tential predictors in a statistically sound way.
 ► The data for this study comes from a voluntary reg-
istry, and the differences between the registry pop-
ulation and the general population of patients with
inflammatory bowel disease (IBD) are unknown.
 ► The models were validated using a test data set
from the same registry and have not yet been vali-
dated in an external cohort of individuals with IBD.
 ► Our methods are associational, not causal—when
using the online risk calculator, healthcare providers
should not use it to answer ‘what- if’ questions (eg,
how an individual’s risk would change if they altered 
the medications they were taking) which are inher-
ently causal questions.
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Janus- kinase inhibitors, which are linked with a higher 
risk of viral infection.7 8 Demographics, comorbidities, 
medication use, geographic region and other factors may 
increase the risk for COVID- 19- related complications 
among patients with IBD.9 10 To help healthcare providers 
and patients navigate these myriad potential risk factors, 
we developed and validated penalised multivariable 
logistic regression models for predicting the probability 
of hospitalisation, intensive care unit (ICU) admission 
and death due to COVID- 19 in patients with IBD. We used 
an international registry of 2709 patients with IBD with 
COVID- 19 from 59 countries. We also developed a free, 
publicly available personalised risk calculator using the 
final models that is available online (https:// covidibd. 
org/ covid- 19- risk- calculator/). Reporting follows Trans-
parent Reporting of a multivariable prediction model for 
Individual Prognosis or Diagnosis guidelines.11
METHODS
Source of data
The Surveillance Epidemiology of Coronavirus Under 
Research Exclusion for Inflammatory Bowel Disease 
(SECURE- IBD) database ( www. covidibd. org) is an inter-
national registry to study outcomes of COVID- 19 in 
paediatric and adult patients with IBD.12 SECURE- IBD is 
a voluntary registry with ongoing data collection where 
healthcare providers can report cases of COVID- 19 in 
patients with IBD, confirmed by PCR or antibody testing. 
Healthcare providers are instructed to report cases of 
severe outcomes after a minimum of 7 days from the 
onset of symptoms and after a sufficient time has passed 
to observe the disease course through the resolution of 
acute illness or death. In the event that a patient’s status 
changed after submission, reporters are instructed to 
re- report and contact the research team. Reporters were 
not explicitly informed of what data could be used as 
predictors or outcomes, but being a voluntary registry, 
reporters were not blinded. A fuller account of the data 
collection is given in Brenner et al.13
Patient
Patient and professional organisations representing many 
countries were engaged in planning the registry and the 
data collection, promoting the registry and disseminating 
results from studies using the SECURE- IBD database. A 
list of the organisations involved is available in online 
supplemental table 1.
Participants
We included all patients reported to the registry from 13 
March 2020, the data collection start date, through 20 
October 2020. For model development, a training sample 
consisting of 85% of the entire surveillance data set avail-
able as of 15 September 2020 was used. The random 
split was done using stratified random sampling based 
on an ordinal version of the outcome. The test data set 
consisted of the remaining 15% of the data available on 
15 September, plus all of the additional cases reported to 
the registry between 16 September 2020 and 20 October 
2020. We added the entirety of the last month of data to 
the test data set in order to provide a more honest assess-
ment of our model’s performance in an environment that 
is changing over time.
We reported means and SD for continuous variables, 
counts for categorical variables and proportions for 
binary variables. We reported the missing data for all 
variables. We did not include p values in our descrip-
tive tables following the Strengthening the Reporting of 
Observational Studies in Epidemiology guidelines.14
Outcomes
We examined three primary outcomes: (1) hospitalisation 
or death (Hospitalisation+), (2) ICU admission, mechan-
ical ventilation or death (ICU+) and (3) death due to 
COVID- 19 related causes (Death). Patients may experi-
ence multiple outcomes. All outcomes were reported by 
the patient’s healthcare provider at the time of the case 
report.
Predictors
As our aim was to create models and a risk stratification
tool intended to allow physicians to inform patients of
their risk before presenting with COVID- 19, we restricted
our attention to predictors that would be available during
a routine consultation. COVID- 19 presenting symptoms
and information about the COVID- 19 treatment received
were therefore not included in this analysis. All predictors
were reported by the patients’ healthcare provider.
A full description of the predictors is available in
online supplemental table 2. Demographic predictors
included age, country of residence, state of residence
(for US cases), gender, race and ethnicity. Racial indica-
tors included white, black and Asian. American Indian
and Pacific Islander indicators were excluded due to low
prevalence. Multi- racial patients belong to multiple cate-
gories. As only one patient had reported a gender other
than male or female, only two genders were considered
in the analysis. Due to the nature of reporting, ethnicity,
gender and race should be interpreted as provider-
perceived race and gender. Assessing race and ethnicity
is important for identifying potential health inequities
in COVID- 19 related outcomes. For cases from US states
with very low prevalence in the registry, a more general
geographic predictor (census region or census division)
was used in place of the state itself. Clinical predictors
included height, weight, body mass index (BMI, study
derived), IBD diagnosis (Crohn’s disease, ulcerative colitis 
or IBD unspecified) and IBD disease activity as defined by
physician global assessment. We included indicators for
the following a priori defined medication classes: biolog-
icals (including antitumour necrosis factor (anti- TNF),
anti- interleukin 12 (anti- IL- 2) and anti- integrin agents),
5- aminosalicylates/sulfasalazine, immunomodulators 
(6MP, azathioprine, methotrexate), corticosteroids
(prednisone, budesonide and other oral/parenteral
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Table 1 Main characteristics of COVID- 19 inflammatory bowel disease patients in the study*
Characteristics Training data (n=2009) Test data (n=700) Overall (n=2709)
Age, mean (SD), years 42.2 (18.2) 38.7 (17.4) 41.2 (18.0)
Gender, n (%)
 Female 982 (48.9%) 344 (49.1%) 1326 (48.9%)
 Male 998 (49.7%) 341 (48.7%) 1339 (49.4%)
 Other 1 (0.0%) 0 (0.0%) 1 (0.0%)
Asian†, n (%) 112 (5.6%) 38 (5.4%) 150 (5.5%)
Black†, n (%) 138 (6.9%) 39 (5.6%) 177 (6.5%)
White†, n (%) 1603 (79.8%) 547 (78.1%) 2150 (79.4%)
Hispanic/Latino, n (%) 350 (17.4%) 115 (16.4%) 465 (17.2%)
 Missing 375 (18.7%) 120 (17.1%) 495 (18.3%)
BMI, mean (SD) 26.0 (6.50) 25.2 (6.26) 25.8 (6.44)
 Missing 398 (19.8%) 106 (15.1%) 504 (18.6%)
Current smoker, n (%) 61 (3.0%) 25 (3.6%) 86 (3.2%)
Disease type, n (%)
 Crohn’s disease 1115 (55.5%) 401 (57.3%) 1516 (56.0%)
 Ulcerative colitis 854 (42.5%) 278 (39.7%) 1132 (41.8%)
Cardiovascular disease, n (%) 133 (6.6%) 43 (6.1%) 176 (6.5%)
Diabetes, n (%) 117 (5.8%) 30 (4.3%) 147 (5.4%)
Hypertension, n (%) 243 (12.1%) 67 (9.6%) 310 (11.4%)
Count of comorbidities, mean (SD) 0.544 (0.938) 0.479 (0.879) 0.527 (0.923)
Biological therapy, n (%) 1203 (59.9%) 437 (62.4%) 1640 (60.5%)
Tumour necrosis factor inhibitor, n (%) 796 (39.6%) 313 (44.7%) 1109 (40.9%)
Anti- integrin, n (%) 213 (10.6%) 72 (10.3%) 285 (10.5%)
IL- 12/23 inhibitor, n (%) 187 (9.3%) 47 (6.7%) 234 (8.6%)
5- Aminosalicylates, n (%) 636 (31.7%) 200 (28.6%) 836 (30.9%)
Sulfasalazine, n (%) 64 (3.2%) 24 (3.4%) 88 (3.2%)
Mesalamine, n (%) 561 (27.9%) 175 (25.0%) 736 (27.2%)
Immunomodulators, n (%) 459 (22.8%) 140 (20.0%) 599 (22.1%)
 Methotrexate, n (%) 81 (4.0%) 24 (3.4%) 105 (3.9%)
Azathioprine or 6- mercaptopurine, n (%) 367 (18.3%) 110 (15.7%) 477 (17.6%)
Corticosteroids, n (%) 209 (10.4%) 65 (9.3%) 274 (10.1%)
Budesonide, n (%) 59 (2.9%) 17 (2.4%) 76 (2.8%)
Oral or parenteral steroids, n (%) 154 (7.7%) 49 (7.0%) 203 (7.5%)
Janus kinase inhibitors (tofacitinib), n (%) 30 (1.5%) 9 (1.3%) 39 (1.4%)
Hospitalisation+, n (%) 499 (24.8%) 138 (19.7%) 637 (23.5%)
 Missing 37 (1.8%) 17 (2.4%) 54 (2.0%)
ICU+, n (%) 133 (6.6%) 36 (5.1%) 169 (6.2%)
 Missing 49 (2.4%) 22 (3.1%) 71 (2.6%)
Death, n (%) 57 (2.8%) 12 (1.7%) 69 (2.5%)
 Missing 33 (1.6%) 14 (2.0%) 47 (1.7%)
*Missingness is only reported for predictors with >5% missing values, and for all outcomes. Only comorbidities with an overall prevalence
above 5% are shown in this table. For a complete list of characteristics and number and percentage of missing values, see online
supplemental table 3.
†Individuals can be assigned to more than one physician- reported racial group (white, black, Asian).
BMI, body mass index; ICU, intensive care unit; IL, interleukin.
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steroids) and Janus kinase inhibitors (tofacitinib). We 
also included indicators for subclasses of biologicals (eg, 
anti- TNF) at the time of COVID- 19 diagnosis. Addition-
ally, dosage information was included for prednisone, 
6- mercaptopurine and azathioprine.
For categorical (including binary) predictors without
a meaningful reference level, all levels were included 
in the model. Quadratic terms were considered for 
all continuous covariates. Interactions were consid-
ered based on a combination of subject matter expert 
advice and a minimum threshold of thirty observations 
for every cell for interactions involving two binary 
predictors.
Missing data
Multiple imputation of the covariates and outcomes 
was performed using multivariate imputation by 
chained equations to address missing data.15 16 A total 
of 30 imputed data sets were created. Imputation was 
performed separately on the training and test data to 
prevent inducing dependence between the training 
and the test data through the imputation models. For 
transformed variables that are derived from other 
covariates (eg, BMI from height and weight), we 
imputed the missing root variables and then created 
the transformed variable to ensure that the relation-
ship between the transformed variable and its inputs 
was preserved.
Table 1 includes the level of missing data in each 
of the covariates included in the analysis. Medication 
variables, clinical descriptions of disease and severity, 
location, age, and gender all had very low levels of 
missingness, ranging from 0% to under 5%. There were 
three covariates with a moderate amount of missing 
data—height, weight and ethnicity were missing in 
approximately 20% of patients.
Statistical analysis
The 10- fold cross- validation deviance averaged across 
each of the imputed data sets was used to decide 
between the least absolute shrinkage and selection 
operator (LASSO), ridge or elastic net penalties and 
to choose the value of the regularisation parameter.17 18 
Separate logistic regression models were fit for each 
of the outcomes. Smoothing splines for continuous 
covariates,19 a multinomial model, Group LASSO20 and 
Sparse Group LASSO,21 were all investigated as poten-
tial methods, but the performance improvement in 
terms of the cross- validation deviance was not sufficient 
to justify the additional complexity and computational 
time. The non- parametric resampling bootstrap was 
used to generate 1000 samples, and for each bootstrap 
sample, the same sampled participants were used across 
the 30 imputed data sets.22 A total of 30 000 (30×1000) 
fitted models were created. Predicted probabilities were 
created by averaging the predictions from all models. 
We used the sample mean of the bootstrap distribution 
of the predicted probabilities for the final predicted 
probability and the percentiles of the bootstrap distri-
bution to find the 90% CI for the risk estimate. Risk 
groups were not created.
To assess the performance of the resulting predic-
tions, we created receiver operator characteristic (ROC) 
curves and calculated the corresponding area under 
the curve (AUC) using the held- out test data set for the 
imputed data sets.22 We provide two graphical summa-
ries of the resulting models: (1) a summary of the sign 
distribution showing, across bootstrap replications and 
imputed data sets, the proportion of estimated associ-
ations which were negative (better outcomes), zero or 
positive and (2) box plots of the estimated effect on 
the log- odds scale. We opted to show box plots instead 
of CIs to highlight the exploratory nature of the results 
for individual predictors. LASSO estimates are biased, 
and the lack of a priori hypotheses makes statistical 
significance testing inappropriate. We first defined a 
set of contrasts in order to make meaningful compar-
isons while accounting for the second- order terms in 
the model rather than report results for every param-
eter. The contrast matrices are available on a public 
repository (https:// github. com/ KosorokLab/ CovidIB-
DRiskCalc) in a CSV format.
Predictions are averaged over bootstrap replications 
and imputed data sets, and so there is no single set of 
model coefficients to report. Because the logistic link 
function is non- linear, the predicted probability from 
averaging over predictions from each fitted model does 
not equal the predicted probability from averaging 
over coefficients across the models. Additionally, aver-
aging the model coefficients would result in none of the 
Figure 1 ROC curves for Hospitalisation+, ICU+ and Death 
showing the models’ sensitivities as a function of their 
specificity (axis reversed). AUC, area under the curve; ICU, 
intensive care unit; ROC, receiver operator characteristic.
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coefficients being equal to zero unless that coefficient is 
equal to zero in every fitted model. Instead of reporting 
a misleading model summary, we opted to make all the 
model coefficients available online (https:// github. com/ 
KosorokLab/ CovidIBDRiskCalc).
Software
The analysis was conducted using R V.4.0.2 and the 
tidyverse, glmnet, glmnetUtils, mice, magrittr, future and 
pROC packages.16 23–29 The online calculator was created 
using shiny.30 The most recent draw for the Carolina 
Pick 4 lottery (https:// nclottery. com/ Pick4) at the time 
of analysis was used for the random number generation 
seed. The code used to conduct the analysis is available 
on GitHub (https:// github. com/ KosorokLab/ CovidIB-
DRiskCalc). This does not include the study data, but 
the estimated model coefficients are available.
Figure 2 Estimated contrast sign distribution showing the proportion of times the estimated association was positive, negative 
or zero. IBD, inflammatory bowel disease; COPD, chronic obstructive pulmonary disease; IL, interleukin; TNF, tumour necrosis 
factor.




A total of 2709 patients were reported to the registry, split 
into a training set of 2009 patients and a test data set of 
700 patients. The test data set was comprised 366 from 
the 15% split and 334 patients added to the registry after 
model fitting and before manuscript submission. Table 1 
provides demographic, clinical, medication and outcome 
descriptive summaries for the training set, test set and the 
whole sample. A total of 633 (24%) patients were hospi-
talised, 137 (5%) were admitted to the ICU or intubated 
and 69 (3%) patients died. The cohort has 1076 (40%) 
patients from the USA, with the rest coming from a variety 
of other countries summarised in table 1.
Model performance
The models have excellent discrimination, with an AUC 
and associated 95% CI estimated on the test data set 
averaged over the imputations of 0.79 (0.75 to 0.83) for 
Hospitalisation+, 0.88 (0.82 to 0.95) for ICU+ and 0.94 
(0.89 to 0.99) for Death. The receiver operator character 
curves are shown in figure 1.
Predictors of hospitalisation, intensive care and death
Figures 2 and 3 show the estimated coefficient sign distri-
bution and the effect on the log- odds scale for the ten 
contrasts most strongly associated with each outcome, 
respectively. Consistent with other studies on risk factors 
for hospitalisation and death, we find older age, male 
Figure 3 Estimated contrast effect size distribution box plots where the effects are shown on the log- odds scale. COPD, 
chronic obstructive pulmonary disease; IBD, inflammatory bowel disease; IL, interleukin; TNF, tumour necrosis factor.
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gender and comorbidities to be associated with worse 
outcomes due to COVID- 19.3 31 White race is associated 
with a lower risk of Hospitalisation+ in 89.2% of our repli-
cations but is not consistently selected in the models for 
ICU+ (30%) or Death (10%). These plots, not restricted 
to the top ten effects, are available in the supplement 
for all demographic, clinical and medication predictors 
(online supplemental figures 1 and 2), for countries 
(online supplemental figures 3 and 4) and for US regions 
(online supplemental figures 5 and 6).
Corticosteroids are associated with a higher risk of 
Hospitalisation+, ICU+ and Death. Oral corticosteroid 
use is the most important predictor, in terms of the 
magnitude of the absolute value of the coefficient, for 
Hospitalisation+, ICU+ and Death (figure 3). Biological 
medicines are associated with a lower risk of Hospitalisa-
tion+, ICU+ and Death, with integrin antagonists having 
directionally smaller effects than TNF antagonists or 
IL- 12/23 inhibitors.
Online risk tool
The online risk calculator where physicians can enter 
their patient’s information and receive predictions 
from our models is freely available online (http:// shiny. 
bios. unc. edu/ secure- ibd- risk- calc/). The SECURE- IBD 
COVID- 19 Risk Calculator was designed for physicians to 
use during consultations with their patients and includes 
detailed clinical characteristics, including demographics, 
disease diagnosis information, comorbidities and current 
medications. Daily dosage may optionally be entered for 
certain medications. The output of the risk calculator 
numerically and visually summarises the patient’s prob-
abilities of adverse outcomes and associated prediction 
intervals among the three nested outcomes discussed 
earlier. Figures 4 and 5 display the results for two example 
patients and their associated probabilities (and 90% CIs) 
of adverse outcomes if they were to contract COVID- 19. 
The interactive application could provide a reliable basis 
for distinguishing between high- risk and low- risk patients 
to aid in personalising clinical guidance on decisions 
about precautions, returning to normal activities and 
vaccination.
DISCUSSION
We developed and validated risk prediction models for 
hospitalisation, intensive care stay and death resulting 
from COVID- 19 in patients with IBD using data from 
2709 cases from 59 countries reported through an inter-
national voluntary registry.12 We made a free online risk 
calculator using these models (https:// covidibd. org/ 
covid- 19- risk- calculator/) for healthcare providers to 
facilitate discussion of risks due to COVID- 19 with their 
patients with IBD.4 The interactive application could 
Figure 4 Online risk prediction tool example for a patient with below- average predicted risk. Young age, gender and a lack of 
comorbidities contribute to a lower- than- average risk of adverse COVID- 19 outcomes. IBD, inflammatory bowel disease; ICU, 
intensive care unit.
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provide a reliable basis for distinguishing between high- 
risk and low- risk patients to aid in personalising clinical 
guidance on decisions about precautions, returning to 
normal activities and vaccination.
Other COVID- 19- related risk prediction tools have 
focused on predicting hospital course based on clinical 
data captured at the time of admission,6 and predicting 
mortality among US patients aged 65 years and older.5 
Our risk tool is unique in at least three ways. First, we 
focus on a specialised population of patients with IBD, a 
chronic, immune- mediated condition frequently treated 
with immune suppressive medications and often affected 
by other comorbidities. Second, our model focuses 
on predictors that are known before a patient were to 
contract COVID- 19 and thus can be used to inform life-
style or treatment decisions to prevent infection or down-
stream complications. Finally, we examine a broader 
range of outcomes than tools focused solely on mortality. 
Our work can serve as a model for other disease areas, and 
our code is publicly available and could be adapted for 
similar online risk tools in other settings or populations.
Strong associations with worse adverse COVID- 19 
outcomes were oral corticosteroids, older age, comor-
bidities, gender and non- white physician- reported race 
(for Hospitalisation+). Caution must be used when 
interpreting penalised regression results because the 
coefficients are biased, but the results for oral cortico-
steroids were particularly dramatic. Compared with not 
taking an oral corticosteroid, taking a daily dose equiva-
lent of 40 mg of prednisone was associated with 10 times 
greater adjusted odds of death. Biological therapies 
were associated with a lower risk of adverse COVID- 19 
outcomes, with small differences between the subcatego-
ries of biological therapies. Compared with not taking a 
biological therapy, TNF inhibitors were associated with 
an adjusted OR of 0.62 for death. In contrast to earlier 
studies using this database,13 32 we did not find a consis-
tent association between 5- aminosalicylates and a higher 
risk of adverse outcomes; depending on the imputation 
and bootstrap replication, the sign would often change 
from positive to negative.
The worldwide collaboration that enabled this study and 
the detailed clinical data reported by physicians or trained 
medical staff is an important strength of this study. The 
machine learning approach allowed us to consider a wide 
variety of potential associations with adverse outcomes, 
and we examined multiple adverse COVID- 19- related 
adverse outcomes enabling preliminary comparisons 
between risks. Certain comorbidities, including chronic 
obstructive pulmonary disease (COPD), cardiovascular 
Figure 5 Online risk prediction tool example for a patient with above- average predicted risk. Older age, prednisone dosage 
and hypertension were the major contributors to increased risk, with ethnicity having a small positive association with increased 
risk. IBD, inflammatory bowel disease; ICU, intensive care unit.
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disease (CVD), and cancer, were not as strongly associated 
with Hospitalisation+ as they were for death. In contrast, 
severe IBD disease activity was an important predictor of 
Hospitalisation+ but was not consistently associated with 
a higher risk of ICU+ or Death.
Limitations
The data for this study comes from a voluntary registry, and 
the registry population may differ in unknown ways from 
the general population of patients with IBD. Reported 
cases may under- represent both low- risk asymptomatic 
cases and severely ill patients who may be hospitalised at 
an outside hospital or die without their healthcare provid-
er’s knowledge. Model development and validation were 
conducted using data from the same registry, and valida-
tion in an independent cohort of patients with IBD will 
be an important future direction. Our results are associa-
tional, not causal—when using the online risk calculator, 
healthcare providers should not use it to answer ‘what- 
if’ questions (eg, how an individual’s risk would change 
if they altered the medications they were taking) which 
are inherently causal questions.33 While the registry has a 
wealth of clinical data, it does not collect granular data on 
many social determinants of health. Additionally, insur-
ance status is not collected, which, for patients in the 
USA, likely factors into the decision making of whether 
to visit a hospital. Finally, we cannot compare the risk of 
adverse COVID- 19 outcomes in patients with IBD to that 
in the general population.
CONCLUSIONS
This prognostic model can effectively predict which 
patients with IBD may be at higher risk for COVID- 
19- related morbidity. The free and publicly available 
(https:// covidibd. org/ covid- 19- risk- calculator/) risk 
calculator should facilitate patient–provider discussions 
regarding the individualised risk of COVID- 19 based on 
patient and treatment- related factors. As COVID- 19 cases 
continue to rise in the USA and the rest of the world, this 
tool will be important in assisting physicians in identifying 
high- risk patients with downstream clinical implications. 
This tool can inform public health efforts to promote 
rational vaccine allocation and could help providers 
target their outreach to higher- risk patients. We believe 
this approach can also serve as a model for risk stratifica-
tion in other chronic diseases.
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